top of page
Title | Disease Type | Location | SolidTumor | Description | RegulatoryLink |
|---|---|---|---|---|---|
MR2021.03 | Advanced Malignancies | Salt Lake City, UT | A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients with Advanced Malignancies | https://clinicaltrials.gov/ct2/show/NCT05391022?term=CPI+0610-05&draw=2&rank=1 | |
MR2020.06 | NSCLC & Solid Tumors | Salt Lake City, UT | Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors | https://clinicaltrials.gov/ct2/show/NCT04868877?term=MCLA-129-CL01&draw=2&rank=1 | |
MR2021.09 | Solid Tumors | Salt Lake City, UT
Grand Rapids, MI | An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 and INBRX-105 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT03809624?term=Ph1+INBRX-105&draw=2&rank=1 | |
MR2021.10 | Solid Tumors | Salt Lake City, UT
San Antonio, TX
Grand Rapids, MI | A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies | https://clinicaltrials.gov/ct2/show/NCT05006794?term=GS-US-467-5643&draw=2&rank=1 | |
MR2021.11 | Ovarian | Salt Lake City, UT
Grand Rapids, MI | Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L) Administered Intravenously in Subjects with Ovarian Cancer | https://clinicaltrials.gov/ct2/show/NCT04406623?term=SL03-OHD-101&draw=2&rank=1 | |
MR2021.07 | Solid Tumors | Salt Lake City, UT | A Phase 1a/1b Study of LY3537982 Administered to Patients with Advanced Solid Tumors with KRAS G12C Mutation | https://clinicaltrials.gov/ct2/show/NCT04956640?term=LOXO-RAS-20001&draw=2&rank=1 | |
MR2021.17 | Solid Tumors | Salt Lake City, UT
San Antonio, TX
Grand Rapids, MI | Phase 1/2 First-in-Human (FIH) Study of Leukocyte ImmunoglobulinLike Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies | https://clinicaltrials.gov/ct2/show/NCT04669899?term=JTX-8064-101&draw=2&rank=1 | |
MR2021.18 | Solid Tumors | Salt Lake City, UT | A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05208762?term=SGNPDL1V-001&draw=2&rank=1 | |
MR2021.19 | Prostate Cancer | Salt Lake City, UT | A Phase 2 Trial of SRF617 in Combination With AB928
(Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer | https://clinicaltrials.gov/ct2/show/NCT05177770?term=SRF617-201&draw=2&rank=1 | |
MR2021.20 | Solid Tumors | Salt Lake City, UT
Grand Rapids, MI | Clinical and Immunologic Activity of Nemvaleukin Alfa with a Less Frequent IV Dosing Schedule as Monotherapy and in Combination with Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients (ARTISTRY-3) | https://clinicaltrials.gov/ct2/show/NCT04592653?term=ALKS+4230-003&draw=2&rank=1 | |
MR2021.21 | Solid Tumors | Salt Lake City, UT
San Antonio, TX
Grand Rapids, MI
Madrid, Spain | A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05194072?term=SGNB7H4V-001&draw=2&rank=1 | |
MR2022.02 | Solid Tumors | Salt Lake City, UT | A Phase 1, Open-label, Dose-escalation Study to Assess
Safety and Pharmacokinetics of nab-Sirolimus in Patients with Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | http://N/A | |
MR2022.03 | Solid Tumors | Salt Lake City, UT | A Phase 1b/2, Dose-confirming, Multipart, Multicenter Study of CFI-402257 as a Single Agent in Advanced Solid Tumors and in Combination with Fulvestrant in Patients with ER+/HER2- Advanced Breast Cancer after Disease Progression on Prior CDK4/6 and Endocrine Therapy | https://clinicaltrials.gov/ct2/show/NCT05251714?term=TWT-203&draw=2&rank=1 | |
MR2022.04 | Solid Tumors | Salt Lake City, UT
Grand Rapids, MI | A Phase 1 Study of SGN-ALPV in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05229900?term=SGNALPV-001&draw=2&rank=1 | |
MR2022.13 | Ovarian; Endometrial; NSCLC; Breast; Mesothelioma | Salt Lake City, UT | Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05579366?term=PRO1184-001&draw=2&rank=1 | |
MR2022.14 | Solid Tumors | Salt Lake City, UT | Expanded Access Program (EAP) to Provide nab-Sirolimus to Patients with Locally Advanced or Metastatic Solid Tumors Enrolled Previously in the HEP-001 Study | http://N/A | |
MR2020.05 | Solid Tumors | Salt Lake City, UT | A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination with AB122 in Participants with Advanced Malignancies | https://clinicaltrials.gov/ct2/show/NCT04772989?term=ARC-12&draw=2&rank=1 | |
MW2018.04 | Solid Tumors; Lymphoma | Grand Rapids, MI
Salt Lake City, UT | Ph1-2 INBRX-105 An Open-Label, Multicenter, Dose-Escalation, Phase 1/2 Study of INBRX-105 and INBRX-105 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT03809624?term=Ph1+INBRX-105&rank=1 | |
MW2018.05 | Solid Tumors; Sarcomas | Grand Rapids, MI | An Open-Label, Multicenter, First-in-Human, Phase 1 Dose Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas | https://clinicaltrials.gov/ct2/show/NCT03715933?term=Ph1+INBRX-109&rank=1 | |
MW2018.22 | Solid Tumors | Grand Rapids, MI
San Antonio, TX
Madrid, Spain | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT03845166?term=XL092-001&rank=1 | |
MW2018.25 | Solid Tumors | Grand Rapids, MI
Madrid, Spain | First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors | https://clinicaltrials.gov/ct2/show/NCT03917381?term=GCT1046-01&draw=2&rank=1 | |
MW2019.07 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A Phase 1/2 Study of CPI-0209 in Patients with Advanced Solid Tumors and Lymphomas | https://clinicaltrials.gov/ct2/show/NCT04104776?term=0209-01&draw=2&rank=1
| |
MW2019.09 | Solid Tumors | Grand Rapids, MI | An Open-Label, Multicenter, First-in-Human, Dose‑Escalation, Phase 1 Study of INBRX‑106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04198766?term=Ph1+INBRX-106&draw=2&rank=1 | |
MW2019.16 | Solid Tumors | Grand Rapids, MI | A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies
| https://clinicaltrials.gov/ct2/show/NCT04152499?term=KL264-01&draw=2&rank=1 | |
MW2019.19 | Solid Tumors | Grand Rapids, MI | An Open-Label Study of ALPN-202 in Subjects with Advanced Malignancies | https://clinicaltrials.gov/ct2/show/NCT04186637?term=AIS-B01&draw=2&rank=1 | |
MW2019.21 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select, Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04247126?term=SY-5609-101&draw=2&rank=1 | |
MW2019.23 | Prostate | Grand Rapids, MI
San Antonio, TX | A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676, an Oral Ligand-directed Degrader (LDD) of the Androgen Receptor (AR), in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC) | https://clinicaltrials.gov/ct2/show/NCT04428788?term=CC-94676-PCA-001&draw=2&rank=1 | |
MW2019.26 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2 Expressing Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04278144?term=BBI-20201001&draw=2&rank=1 | |
MW2019.28 | Solid Tumors | Grand Rapids, MI | A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies | https://clinicaltrials.gov/ct2/show/NCT04354246?term=CPG-02-101&draw=2&rank=1 | |
MW2020.02 | Solid Tumors | Grand Rapids, MI
Madrid, Spain | An Exploratory, Open-label, Multicenter Phase 1b Trial to Evaluate Safety and Efficacy of Sym021 (Anti-PD 1) in Combination with Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) or Sym023 and Irinotecan in Patients with Selected Solid Tumor Malignancies
| https://clinicaltrials.gov/ct2/show/NCT04641871?term=Sym021-02&draw=2&rank=1 | |
MW2020.03 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b | https://clinicaltrials.gov/ct2/show/NCT04907968?term=XMT-1536&draw=2&rank=3 | |
MW2020.04 | Solid Tumors | Grand Rapids, MI | A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies | https://clinicaltrials.gov/ct2/show/NCT04092673?term=eFT226-0002&draw=2&rank=1 | |
MW2020.08 | Solid Tumors | Grand Rapids, MI | A Phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors | https://clinicaltrials.gov/ct2/show/NCT04478279?term=ST101-101&draw=2&rank=1 | |
MW2020.12 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04344795?term=TPST-1495-001&draw=2&rank=1 | |
MW2020.14 | Solid Tumors | Grand Rapids, MI | A Phase I Study of REGN6569, an anti-GITR mAb, with cemiplimab in patients with advanced solid tumor malignancies.
| https://clinicaltrials.gov/ct2/show/NCT04465487?term=R6569-ONC-1933&draw=2&rank=1 | |
MW2020.18 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A Phase 1a/1b Open Label, Multi-center Study of the Safety, Pharmacokinetics and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Subjects with Metastatic Solid Tumors
| https://clinicaltrials.gov/ct2/show/NCT04666688?term=LYT-200-2020-01&draw=2&rank=1 | |
MW2020.20 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A First In-Human, Phase 1/2 Study of CFI-402411, Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies | https://clinicaltrials.gov/ct2/show/NCT04521413?term=TWT-101&draw=2&rank=1 | |
MW2020.21 | Solid Tumors | Grand Rapids, MI | Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET gene abnormalities. | https://clinicaltrials.gov/ct2/show/NCT04683250?term=HM06-19-26&draw=1&rank=1 | |
MW2020.24 | Solid Tumors | Grand Rapids, MI | A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04626635?term=R7075-ONC-2009&draw=2&rank=1 | |
MW2020.25 | SCLC, NSCLC, Ovarian, & Breast | Grand Rapids, MI | Phase 1/2A Dose Escalation and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy | https://clinicaltrials.gov/ct2/show/NCT04553133?term=C4161001&draw=2&rank=1 | |
MW2020.27 | Solid Tumors | Grand Rapids, MI | A Phase 1, Open-Label, Multicenter Trial Investigating the Safety Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies | https://clinicaltrials.gov/ct2/show/NCT04672434?term=Sym024-01&draw=2&rank=1 | |
MW2020.28 | Solid Tumors | Grand Rapids, MI | A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and as Part of Combination Therapy in Participants with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04557449?term=C4391001&draw=2&rank=1 | |
MW2020.35 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A Phase 1 Study of SGN-STNV in Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04665921?term=SGNSTNV-001&draw=2&rank=1 | |
MW2020.36 | Solid Tumors | Grand Rapids, MI | A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies | https://clinicaltrials.gov/ct2/show/NCT04485013?term=TTX-080-001&draw=2&rank=1 | |
MW2020.39 | Solid Tumors | Grand Rapids, MI
San Antonio, TX
Salt Lake City, UT | JTX-8064-101: Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
| https://clinicaltrials.gov/ct2/show/NCT04669899?term=JTX-8064-101&draw=2&rank=1 | |
MW2020.43 | Solid Tumors | Grand Rapids, MI | A Phase 1, Open-Label, Multi-center, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Anti-Tumor Activity of PF-07284892 (ARRY-558) as a Single Agent and in Combination Therapy in Participants with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04800822?term=C4481001&draw=2&rank=1 | |
MW2021.04 | Solid Tumors | Grand Rapids, MI | A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | https://clinicaltrials.gov/ct2/show/NCT04913337?term=NGM707+%2B%2F-+Pembrolizumab&draw=2&rank=1 | |
MW2021.09 | Multiple Myeloma | Grand Rapids, MI
Madrid, Spain | A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory
Multiple Myeloma (RRMM)–DREAMM5. | https://clinicaltrials.gov/ct2/show/NCT04126200?term=208887&draw=2&rank=1 | |
MW2021.10 | Solid Tumors | Grand Rapids, MI
San Antonio, TX
Salt Lake City, UT | A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies | https://clinicaltrials.gov/ct2/show/NCT05006794?term=GS-US-467-5643&draw=2&rank=1 | |
MW2021.14 | Solid Tumors | Grand Rapids, MI
Madrid, Spain | A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients with Advanced Solid Tumors
| https://clinicaltrials.gov/ct2/show/NCT04706962?term=TH1902-CTR-0001&draw=2&rank=1 | |
MW2021.17 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05117476?term=CLN-619-001&draw=2&rank=1 | |
MW2021.21 | Solid Tumors | Grand Rapids, MI | A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05215574?term=831-IO-101&draw=2&rank=1 | |
MW2021.23 | Solid Tumors | Grand Rapids, MI | A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04840394?term=BDB018-101&draw=2&rank=1 | |
MW2021.25 | Ovarian Cancer | Grand Rapids, MI | An Open-label, Multicenter, Dose Escalation and Expansion Modular, Umbrella Master Study of
upifitamab rilsodotin in Combination With other Agent(s) In Participants with High-grade Serous
Ovarian Cancer (UPGRADE) | https://clinicaltrials.gov/ct2/show/NCT04907968?term=upifitamab&draw=2&rank=1 | |
MW2021.27 | Solid Tumors | Grand Rapids, MI
Madrid, Spain | A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors | https://clinicaltrials.gov/ct2/show/NCT05029882?term=M21-404&draw=2&rank=1 | |
MW2021.29 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05240898?term=KSQ-4279-1101&draw=2&rank=1 | |
MW2021.33 | Solid Tumors | Grand Rapids, MI
San Antonio, TX
Madrid, Spain | A Phase I, dose finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors that recurred or progressed following prior therapy and/or for whom no standard therapy of
proven benefit is available, followed by an expansion part to assess safety and anti-tumor activity signal. | https://clinicaltrials.gov/ct2/show/NCT05109975?term=Debio+0123-102&draw=2&rank=1 | |
MW2021.34 | Solid Tumors | Grand Rapids, MI | A phase 1, open-label, multicenter, dose-finding study of SKL27969 in patients with advanced solid tumors, central nervous system (CNS) tumors, and hematologic malignancies | https://clinicaltrials.gov/ct2/show/NCT05388435?term=SKL27969C001&draw=2&rank=1 | |
MW2021.35 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | A Phase 1a/1b, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Anti-neoplastic Activity of S095029 (Anti-NKG2A) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies followed by an Expansion Part with Triplet Combinations of S095029 and Sym021 and an anti-HER2 mAb or anti-EGFR mAbs (futuximab/modotuximab) in Patients with Metastatic Gastric or Colorectal cancers | https://clinicaltrials.gov/ct2/show/NCT05162755?term=CL1-95029-001&draw=2&rank=1 | |
MW2021.39 | Solid Tumors | Grand Rapids, MI
San Antonio, TX |
A Phase 1, Open-Label, Dose Escalation and Expansion Study of PF-07265028 as a Single Agent and in Combination with Sasanlimab Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07265028 in Participants with Advanced Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05233436?term=C4731001&draw=2&rank=1 | |
MW2021.41 | Solid Tumors | Grand Rapids, MI | A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05311618?term=438-IO-101&draw=2&rank=1 | |
MW2021.51 | Solid Tumors | Grand Rapids, MI | A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers | https://clinicaltrials.gov/ct2/show/NCT05259696?term=PAL-E602-001&draw=2&rank=1 | |
MW2021.55 | Solid Tumors | Grand Rapids, MI | A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05067283?term=MK-1084-001&draw=2&rank=1 | |
MW2021.58 | Solid Tumors | Grand Rapids, MI | An Exploratory Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients with Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy. | https://clinicaltrials.gov/ct2/show/NCT05054257?term=19-01&draw=2&rank=1 | |
MW2021.59 | Solid Tumors | Grand Rapids, MI | A Phase 1, First-in-Human, Dose Escalation and Expansion Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies | https://clinicaltrials.gov/ct2/show/NCT05362773?term=CP-MGD024-01&draw=2&rank=1 | |
MW2021.60 | Solid Tumors | Grand Rapids, MI | Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study) | https://clinicaltrials.gov/ct2/show/NCT05147272?term=RP-6306-02&draw=2&rank=1 | |
MW2021.63 | Solid Tumors | Grand Rapids, MI
San Antonio, TX
Salt Lake City, UT
Madrid, Spain | A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05194072?term=SGNB7H4V-001&draw=2&rank=1 | |
MW2021.65 | Solid Tumors | Grand Rapids, MI | Clinical and Immunologic Activity of Nemvaleukin Alfa with a Less Frequent IV Dosing Schedule as Monotherapy and in Combination with Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients (ARTISTRY-3) | https://clinicaltrials.gov/ct2/show/NCT04592653?term=ALKS+4230-003&draw=2&rank=1 | |
MW2021.66 | Solid Tumors | Grand Rapids, MI
Salt Lake City, UT | A Phase 1 Study of SGN-ALPV in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05229900?term=SGNALPV-001&draw=2&rank=1 | |
MW2021.68 | Solid Tumors | Grand Rapids, MI | A Phase 1, First in Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05228015?term=IK930-001&draw=2&rank=1 | |
MW2021.69 | Solid Tumors | Grand Rapids, MI | A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05025085?term=C-1400-01&draw=2&rank=1 | |
MW2021.73 | Solid Tumors | Grand Rapids, MI | A Phase 1b/2, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05262400?term=C4391002&draw=2&rank=1 | |
MW2021.74 | Ovarian Cancers | Grand Rapids, MI | An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers | https://clinicaltrials.gov/ct2/show/NCT05483933?term=SL03-OHD-105&draw=2&rank=1 | |
MW2021.75 | Solid Tumors | Grand Rapids, MI | A Phase 1/1b, Open-label, Multicenter, Two-part Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants with Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations | https://clinicaltrials.gov/ct2/show/NCT05242822?term=kn-4802&draw=2&rank=1 | |
MW2022.17 | Solid Tumors & NSCLC | Grand Rapids, MI | A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and
Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer | https://clinicaltrials.gov/ct2/show/NCT05543629?term=BMS-986442&draw=2&rank=1 | |
MW2022.21 | Myelodysplastic Syndrome (MDS) | Grand Rapids, MI | A Phase 1/ 2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) (ASPEN-02) | https://clinicaltrials.gov/ct2/show/NCT04417517?term=AT148002&draw=2&rank=1 | |
MW2022.28 | Myelodysplastic Syndrome (MDS); Acute Myeloid Leukemia (AML) | Grand Rapids, MI | An Open-Label Phase 1a/1b Dose Escalation and Expansion
Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) | https://clinicaltrials.gov/ct2/show/NCT05275439?term=SL-172154&draw=2&rank=4 | |
MW2022.36 | Solid Tumors | Grand Rapids, MI
San Antonio, TX | Protocol Title: A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab, carboplatin, or cisplatin in adult subjects with advanced solid tumors | ||
MW2017.01 | Solid Tumors | Grand Rapids, MI
Madrid, Spain | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET
Activation (LIBRETTO-001) | https://clinicaltrials.gov/ct2/show/NCT03157128?term=LOXO-RET-17001&rank=1 | |
SA2018.08 | Solid Tumors | San Antonio, TX | An open-label, Phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and tumor response profile of the ILDR2 function-blocking antibody BAY 1905254 in patients with advanced solid tumors | https://clinicaltrials.gov/ct2/show/NCT03666273?term=18789&rank=1 | |
SA2018.13 | Solid Tumors | San Antonio, TX | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation | https://clinicaltrials.gov/ct2/show/NCT03785249?term=849-001&rank=1 | |
SA2018.14 | Gastrointestinal Tumors | San Antonio, TX | A first-in-human phase Ia/b, open label, multicentre, dose escalation study of BI 905711 in patients with advanced gastrointestinal cancers | https://clinicaltrials.gov/ct2/show/NCT04137289?term=1412-0001&draw=2&rank=1 | |
SA2018.19 | Solid Tumors | San Antonio, TX | A Multicenter, Open-label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. | https://clinicaltrials.gov/ct2/show/NCT03486873?term=MK-3475-587&rank=1 | |
SA2018.25 | Solid Tumors; Hematologic Cancers | San Antonio, TX | A Phase 1, Open-Label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers | https://clinicaltrials.gov/ct2/show/NCT03783403?term=CC-95251-ST-001&rank=1 | |
SA2018.31 | Solid Tumors | San Antonio, TX
Grand Rapids, MI
Madrid, Spain | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT03845166?term=XL092-001&rank=1 | |
SA2018.32 | Solid tumor | San Antonio, TX | An open-label, Phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and tumor response profile of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in patients with advanced solid tumors | https://clinicaltrials.gov/ct2/show/NCT04069026?term=20201&draw=2&rank=1 | |
SA2019.16 | Solid Tumors | San Antonio, TX | A phase 1 study of SGN-CD228A in select advanced solid tumors | https://clinicaltrials.gov/ct2/show/NCT04042480?term=SGN228-001&draw=2&rank=1 | |
SA2019.18 | Solid Tumors | San Antonio, TX | A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Locally Advanced or Metastatic Cancer | https://clinicaltrials.gov/ct2/show/NCT04130516?term=LNS-101&draw=2&rank=1 | |
SA2019.20 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04104776?term=0209-01&draw=2&rank=1 | |
SA2019.23 | Solid Tumors | San Antonio, TX | A Phase 1 Study of SRF617 in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04336098?term=SRF617-101&draw=2&rank=1 | |
SA2019.27 | Breast | San Antonio, TX
Madrid, Spain | Ember: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers | https://clinicaltrials.gov/ct2/show/NCT04188548?term=J2J-MC-JZLA&draw=2&rank=1 | |
SA2019.30 | Ovarian, Breast, CRC, Lung Cancer | San Antonio, TX
Grand Rapids, MI | A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select, Advanced Solid Tumors
| https://clinicaltrials.gov/ct2/show/NCT04247126?term=SY-5609-101&draw=2&rank=1 | |
SA2019.32 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced and HER2-Expressing Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04278144?term=BBI-20201001&draw=2&rank=1 | |
SA2019.33 | Solid Tumors | San Antonio, TX | A Phase 1, Open-Label to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
| https://clinicaltrials.gov/ct2/show/NCT04648202?term=FS120-19101&draw=2&rank=1 | |
SA2019.36 | Prostate | San Antonio, TX
Grand Rapids, MI | A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676, an Oral Ligand-directed Degrader (LDD) of the Androgen Receptor (AR), in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC) | https://clinicaltrials.gov/ct2/show/NCT04428788?term=CC-94676-PCA-001&draw=2&rank=1 | |
SA2019.38 | Solid Tumors | San Antonio, TX
Madrid, Spain | A Phase 1 Study of SGN-B6A in Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04389632?term=SGNB6A-001&draw=2&rank=1 | |
SA2019.39 | Solid Tumors | San Antonio, TX | A Phase 1/1b Study of SRF388 in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04374877?term=SRF388-101&draw=2&rank=1 | |
SA2019.42 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04344795?term=TPST-1495-001&draw=2&rank=1 | |
SA2020.01 | Solid Tumors | San Antonio, TX | A Phase la/lb, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid
Tumors | https://clinicaltrials.gov/ct2/show/NCT04443088?term=INV-1120-101&draw=2&rank=1 | |
SA2020.03 | Solid Tumors | San Antonio, TX | A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies | https://clinicaltrials.gov/ct2/show/NCT04354246?term=CPG-02-101&draw=2&rank=1 | |
SA2020.05 | Solid Tumors | San Antonio, TX | A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04381650?term=TAK-981-1502&draw=2&rank=1 | |
SA2020.07 | Solid Tumors | San Antonio, TX | A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04446351?term=212214&draw=2&rank=1 | |
SA2015.51 | Solid Tumors | San Antonio, TX
Madrid, Spain | A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects with Advanced Solid Tumors
| https://clinicaltrials.gov/ct2/show/NCT02720068?term=MK-4280-001&rank=1 | |
SA2020.11 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04666688?term=LYT-200-2020-01&draw=2&rank=1 | |
SA2020.14 | Solid Tumors | San Antonio, TX | Phase 1, Two-Part, Multicenter, Open-Label, Multiple Dose, First-in-Human Study of DS-1062a in Subjects with Advanced Solid Tumors
| https://clinicaltrials.gov/ct2/show/NCT03401385?term=DS1062-A-J101&draw=2&rank=1 | |
SA2020.18 | Ovarian, Cervix, Uterine, Vulva, Breast, Lung, Kidney,Colon, or Gastric | San Antonio, TX | A Phase 1a/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination with a Checkpoint Inhibitor in Subjects with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04691375?term=PY314-1-01&draw=2&rank=1 | |
SA2020.20 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A First-In-Human Phase 1/2 Study of CFI-402411, Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies (TWT-101) | https://clinicaltrials.gov/ct2/show/NCT04521413?term=TWT-101&draw=2&rank=1 | |
SA2020.22 | Pancreatic | San Antonio, TX | Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer | https://clinicaltrials.gov/ct2/show/NCT04631445?term=TD2-PDAC-KETO-001&draw=2&rank=1 | |
SA2020.25 | Solid Tumors | San Antonio, TX | A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations
| https://clinicaltrials.gov/ct2/show/NCT04521686?term=LOXO-IDH-20002&draw=2&rank=1 | |
SA2020.26 | NSCLC | San Antonio, TX | A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Immunotherapy with or without Carboplatin in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04) | https://clinicaltrials.gov/ct2/show/NCT04612751?term=DS1062-A-U104&draw=2&rank=1 | |
SA2020.28 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1 Study of SGN-STNV in Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04665921?term=SGNSTNV-001&draw=2&rank=1 | |
SA2020.30 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04626635?term=R7075-ONC-2009&draw=2&rank=1 | |
SA2020.31 | Solid Tumor | San Antonio, TX
Grand Rapids, MI | Phase 1/2 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor in Adult Subjects with Advanced Refractory Solid Tumor Malignancies | https://clinicaltrials.gov/ct2/show/NCT04669899?term=JTX-8064-101&draw=2&rank=1 | |
SA2020.32 | HNSCC & CRC | San Antonio, TX | A Phase 1B/2, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 in Combination with Cetuximab as a Salvage Regiment for Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04616196?term=19-255-03&draw=2&rank=1 | |
SA2020.34 | Solid Tumors | San Antonio, TX
Madrid, Spain | A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as a Single Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04726332?term=XL102-101&draw=1&rank=1 | |
SA2020.37 | Solid Tumor | San Antonio, TX | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04580485?term=INCB+106385-102&draw=2&rank=1 | |
SA2020.38 | Solid Tumors | San Antonio, TX
Madrid, Spain | Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors | https://clinicaltrials.gov/ct2/show/NCT04718675?term=KB-0742-1001&draw=2&rank=1 | |
SA2020.40 | Solid Tumors | San Antonio, TX | A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04682431?term=PY159-2-01&draw=2&rank=1 | |
SA2020.42 | Solid Tumors | San Antonio, TX | A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects with Advanced Solid Malignancies | https://clinicaltrials.gov/ct2/show/NCT05047536?term=KZR-261-101&draw=2&rank=1 | |
SA2020.44 | Solid Tumors | San Antonio, TX | Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT141 as a monotherapy and in combination with other anti-cancer agents in patients with CLDN18.2-positive solid tumors | https://clinicaltrials.gov/ct2/show/NCT04683939?term=BNT141-01&draw=2&rank=1 | |
SA2020.49 | Solid Tumors | San Antonio, TX | A Phase 1/1B Study to Evaluate the Safety and Tolerability of AB308 in Combination with AB122 in Participants with Advanced Malignancies | https://clinicaltrials.gov/ct2/show/NCT04772989?term=ARC-12&draw=2&rank=1 | |
SA2017.18 | Solid Tumors | San Antonio, TX | A Phase 1 Open-label Dose Escalation Study of BDB001 as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT03486301?term=BDB001-101&draw=2&rank=1 | |
SA2021.01 | Solid Tumors | San Antonio, TX | A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 monotherapy and combined with docetaxel in adult subjects with relapsed and refractory solid tumors | https://clinicaltrials.gov/ct2/show/NCT04721015?term=M20-111&draw=2&rank=1 | |
SA2021.06 | Solid Tumors | San Antonio, TX | A Phase 1 Open-label, Multicenter, Dose-ranging Study to
Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1 | https://clinicaltrials.gov/ct2/show/NCT04795713?term=MT-6402-001&draw=2&rank=1 | |
SA2021.07 | Solid Tumors | San Antonio, TX | A Phase 1a/1b Study of LY3537982 Administered to Patients with Advanced Solid Tumors with KRAS G12C Mutation | https://clinicaltrials.gov/ct2/show/NCT04956640?term=LOXO-RAS-20001&draw=2&rank=1 | |
SA2021.08 | Solid Tumors | San Antonio, TX
Grand Rapids, MI
Salt Lake City, UT | A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies | https://clinicaltrials.gov/ct2/show/NCT05006794?term=GS-US-467-5643&draw=2&rank=1 | |
SA2021.09 | Breast | San Antonio, TX | A Phase Ib/III Study of Capivasertib Plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-), Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) | https://clinicaltrials.gov/ct2/show/NCT04862663?term=D361DC00001&draw=2&rank=1 | |
SA2021.12 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors. | https://clinicaltrials.gov/ct2/show/NCT05117476?term=CLN-619-001&draw=2&rank=1 | |
SA2021.14 | Solid Tumors | San Antonio, TX | A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04840394?term=BDB018-101&draw=2&rank=1 | |
SA2021.16 | Solid Tumors | San Antonio, TX | Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies | https://clinicaltrials.gov/ct2/show/NCT05163041?term=BT7480-100&draw=2&rank=1 | |
SA2021.17 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1/2 Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05240898?term=KSQ-4279-1101&draw=2&rank=1 | |
SA2021.19 | Solid Tumors | San Antonio, TX
Madrid, Spain | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT04989387?term=INCA+0186-101&draw=2&rank=1 | |
SA2021.24 | Solid Tumors | San Antonio, TX
Grand Rapids, MI
Madrid, Spain | A Phase 1 study consisting of Part 1 dose escalation to determine the MTD and/or RP2D of Debio 0123 as monotherapy followed by Part 2 dose expansion to assess safety and anti-tumor activity of Debio 0123 administered as repeated dosing in adult patients with advanced solid tumors. | https://clinicaltrials.gov/ct2/show/NCT05109975?term=Debio+0123-102&draw=2&rank=1 | |
SA2021.30 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1, Open-Label, Dose Escalation and Expansion Study of PF-07265028 as a Single Agent and in Combination with Sasanlimab Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07265028 in Participants with Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05233436?term=C4731001&draw=2&rank=1 | |
SA2021.31 | Solid Tumors | San Antonio, TX
Grand Rapids, MI
Salt Lake City, UT
Madrid, Spain | A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05194072?term=SGNB7H4V-001&draw=2&rank=1 | |
SA2021.32 | Solid Tumors | San Antonio, TX | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion | https://clinicaltrials.gov/ct2/show/NCT05245500?term=1719-001&draw=2&rank=1 | |
SA2021.33 | Ovarian, NSCLC, Endometrial, Testicular, Rare tumors and cancers of unknown primary | San Antonio, TX | First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors. | https://clinicaltrials.gov/ct2/show/NCT05262530?term=BNT142-01&draw=2&rank=1 | |
SA2021.35 | Solid Tumors | San Antonio, TX | A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies | https://clinicaltrials.gov/ct2/show/NCT05199272?term=23ME-00610-CLIN-001&draw=2&rank=1 | |
SA2021.36 | Solid Tumors | San Antonio, TX | A Phase 1 First Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors
| https://clinicaltrials.gov/ct2/show/NCT05277051?term=217228&draw=2&rank=1 | |
SA2021.38 | Gastrointestinal Tumors | San Antonio, TX | A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies | https://clinicaltrials.gov/ct2/show/NCT04104672?term=AB680CSP0002&draw=2&rank=1 | |
SA2021.40 | Solid Tumors | San Antonio, TX | A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics,pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors | https://clinicaltrials.gov/ct2/show/NCT05094336?term=20210023&draw=2&rank=1 | |
SA2021.43 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1a/1b, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Anti-neoplastic Activity of S095029 (Anti-NKG2A) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies followed by an Expansion Part with Triplet Combinations of S095029 and Sym021 and an AntiHER2 mAb or Anti-EGFR mAbs (futuximab/modotuximab) in Patients with Metastatic Gastric or Colorectal Cancers | https://clinicaltrials.gov/ct2/show/NCT05162755?term=CL1-95029-001&draw=2&rank=1 | |
SA2021.46 | Solid Tumors | San Antonio, TX | A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05208762?term=SGNPDL1V-001&draw=2&rank=1 | |
SA2021.50 | Solid Tumors | San Antonio, TX | A Phase 1b/2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05394350?term=MK1088-002&draw=2&rank=1 | |
SA2021.52 | Solid Tumors | San Antonio, TX | An Open-label, Dose Escalation and Expansion, Phase 1a/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05070247?term=TAK-500-1001&draw=2&rank=1 | |
SA2022.01 | Solid Tumors | San Antonio, TX | A Phase 1b/2, Dose-confirming, Multipart, Multicenter Study of CFI-402257 as a Single Agent in Advanced Solid Tumors and in Combination with Fulvestrant in Patients with ER+/HER2- Advanced Breast Cancer after Disease Progression on Prior CDK4/6 and Endocrine Therapy | https://clinicaltrials.gov/ct2/show/NCT05251714?term=TWT-203&draw=2&rank=1 | |
SA2022.02 | Solid Tumors | San Antonio, TX | First-in-human dose-escalation and expansion study of the anti-CCR8 antibody BAY 3375968 in combination with pembrolizumab to evaluate the safety, tolerability, and pharmacokinetics in participants with selected advanced solid tumors | https://clinicaltrials.gov/ct2/show/NCT05537740?term=21820&draw=2&rank=1 | |
SA2022.04 | Solid Tumors | San Antonio, TX | A Phase 1, Open-label, Dose-escalation Study to Assess Safety and Pharmacokinetics of nab-Sirolimus in Patients with Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | http://N/A - due to non-qualifying study | |
SA2022.05 | Breast; Solid Tumors | San Antonio, TX | A Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation | https://clinicaltrials.gov/ct2/show/NCT05307705?term=LOXO-PIK-21001&draw=1&rank=1 | |
SA2022.07 | Solid Tumors | San Antonio, TX | An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase zeta inhibitor (DGKzi) BAY 2965501 in participants with advanced solid tumors
| https://clinicaltrials.gov/ct2/show/NCT05614102?term=21948&draw=2&rank=1 | |
SA2022.08 | Solid Tumors | San Antonio, TX | A Phase 1, First-in-Human, Dose-Escalation Study of UCT-03-008 in Participants with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05103046?term=UCT03008-001&draw=2&rank=1 | |
SA2022.12 | Solid Tumors | San Antonio, TX | A Phase 1a/1b, Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05581004?term=GO43860&draw=2&rank=1 | |
SA2022.11 | Solid Tumors; Lung Cancer; Diffuse Large B-cell Lymphoma | San Antonio, TX | A Phase 1/2, Open-Label, Multicenter Study of Oral MRT-2359 in Patients with MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse Large B-Cell Lymphoma | https://clinicaltrials.gov/ct2/show/NCT05546268?term=MRT-2359-001&draw=2&rank=1 | |
SA2022.14 | Solid Tumors | San Antonio, TX | Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05462717?term=RMC-6291-001&draw=2&rank=1 | |
SA2022.19 | Solid Tumors | San Antonio, TX | A Phase 1, First in Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2 | https://clinicaltrials.gov/ct2/show/NCT05514717?term=MER-XMT-2056-1&draw=2&rank=1 | |
SA2022.23 | Solid Tumors | San Antonio, TX | A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy in participants with clear cell renal cell carcinoma and other solid tumors | https://clinicaltrials.gov/ct2/show/NCT05536141?term=ARC-20&draw=2&rank=1 | |
SA2022.24 | Solid Tumors | San Antonio, TX | A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes | https://clinicaltrials.gov/ct2/show/NCT05103358?term=TSC-007&draw=2&rank=1 | |
SA2022.38 | Solid Tumors | San Antonio, TX
Grand Rapids, MI | A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors | https://clinicaltrials.gov/ct2/show/NCT05599984?term=M23-385&draw=2&rank=1 | |
SA2022.40 | Solid Tumor; HNSCC | San Antonio, TX | A Phase 1/2 Study of SRF114 in Patients with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT05635643?term=SRF114-101&draw=2&rank=1 | |
SA2022.43 | Solid Tumors | San Antonio, TX | A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of STC-15, a METTL-3 Inhibitor, in Subjects With Advanced Malignancies | https://clinicaltrials.gov/ct2/show/NCT05584111?term=STC15-22101&draw=2&rank=1 | |
SA2022.48 | Solid Tumors | San Antonio, TX | An Open-Label, Multicenter, Phase 1 Study of Igm-7354 in Adult Participants with Relapsed and/or Refractory Cancer
| http://Pending posting | |
SA2022.50 | Solid Tumors | San Antonio, TX | Expanded Access Program (EAP) to Provide nab-Sirolimus to Patients with Locally Advanced or Metastatic Solid Tumors Enrolled Previously in the HEP-001 Study | http://N/A | |
SA2018.02 | Solid Tumors | San Antonio, TX | A Phase 1 Open-Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT03564691?term=MK-4830-001&rank=1 | |
SA2017.41 | Solid Tumors | San Antonio, TX | A Phase 1/2, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, in Patients with Advanced Malignancies | https://clinicaltrials.gov/ct2/show/NCT03440437?term=FS118-17101&rank=1 | |
SA2017.39 | Solid Tumors | San Antonio, TX | A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors | https://clinicaltrials.gov/ct2/show/NCT03520075?term=ASTX029-01&rank=1 |
bottom of page